Amendment and Reply to Office Action Application No. <u>09/671,658</u> Attorney's Docket No. <u>033347-003</u> Page 3

EXXE

 β . (Amended) The antibody or antigen binding fragment of claim 1, wherein the antibody is a 499E9 antagonist.

7. (Amended) The antibody or antigen binding fragment of claim β , wherein the antigen binding fragment is a F(ab')₂, Fab, or F_v fragment.

10. (Amended) An isolated antibody, or antigen binding fragment thereof, that specifically binds to a polypeptide selected from the group consisting of:

a) a substantially pure or recombinant 499E9 polypeptide exhibiting 100% sequence identity over a length of at least 12 contiguous amino acids to SEQ ID NO: 2;

b) a natural sequence 499E9 of SEQ ID NO:2; and

c) a fusion protein comprising 499E9 sequence

11.9 (New) The antibody of claim 1, wherein the antibody binds to a 499E9 polypeptide with a K_d of at least about 3 μ M.

(New) The antibody, or antigen binding fragment of claim 1, that is conjugated to a detectable label.

(New) The antibody, or antigen binding fragment of claim 12, wherein the detectable label is an enzyme, a fluorescent label, or radioisotope.

(New) An isolated antibody, or antigen binding fragment thereof, that binds to a polypeptide of SEQ ID NO:2.

15. (New) An isolated antibody, or antigen binding fragment thereof, that specifically binds to a polypeptide selected from the group consisting of:

Amendment and Reply to Office Action
Application No. 09/671,658
Attorney's Docket No. 033347-003
Page 4

- (a) a polypeptide that shares a biological activity with mouse 499E9 and an amino acid sequence identity of at least about 60% with SEQ ID NO:2; and
- (b) a polypeptide encoded by nucleic acid sequence that selectively hybridizes with SEQ ID NO:1 under wash conditions of at least 55°C and less than 150 mM salt, wherein said polypeptide shares a biological activity with mouse 499E9.

(New) The antibody, or antigen binding fragment of claim 15, wherein the antibody is polyclonal.

- 17. (New) The antibody, or antigen binding fragment of claim 15, wherein the antibody is monoclonal.
- 18. (New) The antibody or antigen binding fragment of claim 15, wherein the antibody is a 499E9 antagonist.
- 19. (New) The antibody, or antigen binding fragment of claim 15, wherein the antigen binding fragment is a F(ab')₂, Fab, or F_v fragment.
- 20. (New) The antibody, or antigen binding fragment of claim 15, wherein the antibody or fragment binds to the polypeptide with a K_d of at least about 30 μ M.
- 21. (New) The antibody, or antigen binding fragment of claim 15, wherein the antibody or fragment binds to the polypeptide with a K_d of at least about 10 μ M.
- 22. (New) The antibody, or antigen binding fragment of claim 15, wherein the antibody or fragment binds to the polypeptide with a K_d of at least about 3 μ M.

ر) المرس المرس

Amendment and Reply to Office Action Application No. <u>09/671,658</u> Attorney's Docket No. <u>033347-003</u> Page 5

23. (New) The antibody, or antigen binding fragment of claim 15 that is conjugated to a detectable label.

24. (New) The antibody, or antigen binding fragment of claim 23, wherein the detectable label is an enzyme, a fluorescent label, or radioisotope.

- 25. (New) The antibody, or antigen binding fragment of claim 15, wherein the polypeptide shares the amino acid sequence identity of at least about 70% with SEQ ID NO:2.
- 26. (New) The antibody, or antigen binding fragment of claim 15, wherein the polypeptide shares the amino acid sequence identity of at least about 80% with SEQ ID NO:2.
- 27. (New) The antibody, or antigen binding fragment of claim 15, wherein the polypeptide shares the amino acid sequence identity of at least about 90% with SEQ ID NO:2.